Treatment options of the premenstrual dysphoric syndrome – an update

Journal: Die Psychiatrie - Grundlagen und Perspektiven
ISSN: 1614-4864

WPA XVII World Congress of Psychiatry

Issue: 2017 (Vol. 14): Issue 4 2017
Pages: 223-233

Treatment options of the premenstrual dysphoric syndrome – an update

N. Bergemann (1)

(1) Sächsisches Krankenhaus Rodewisch


therapy, antidepressants, Menstrual cycle, premenstrual dysphoric disorder, PMDD, luteal phase


Around 2–6 percent of women of childbearing age suffer from a severe form of the premenstrual syndrome (PMS), the premenstrual dysphoric disorder (PMDS). Its main symptoms are affective instability, irritability, depressive moods and emotional tension, yet a number of other psychological and mental disorders are taken into account to support the diagnosis. The symptoms occur cyclically in the week before menstruation and stay throughout menstruation or until shortly afterwards. The disorders lead to a considerable negative impact on the professional and social life of the affected person. Patients regularly constitute a challenge for the cooperation between psychiatrists and gynecologists. Apart from supportive measures and cognitive behavior-therapy-oriented interventions or supplemental measures therapeutic strategies using different pharmacological and hormonal interventions are being implemented. Both the psychopharmacological treatment, particularly the selective serotonin reuptake inhibitor (SSRI), and the hormonal therapy have shown good results. Despite proven positive effects additional research is required to further improve treatment options.

You may also be interested in...

J. Kauffold

Tierärztliche Praxis Großtiere 2008 36 3: 189-198

H. Zerbe 1, D. K. Zimmermann 1, A. Bendix2

Tierärztliche Praxis Großtiere 2008 36 3: 163-169

U. Korsten-Reck

Die Medizinische Welt 2008 59 3: 93-97